Gut Hormones and Inflammatory Bowel Disease
Obesity-driven inflammation disrupts gut barrier integrity and promotes inflammatory bowel disease (IBD). Emerging evidence highlights gut hormones—including glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), glucose-dependent insulinotropic polypeptide (GIP), peptide YY (PYY), cholec...
Saved in:
| Main Authors: | Jonathan Weng, Chunmin C. Lo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/7/1013 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01) -
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01) -
Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
by: Claire H. Feetham, et al.
Published: (2025-09-01) -
New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01) -
Consistent improvements in liver histology across subgroups in a post hoc analysis of the SYNERGY-NASH trial with tirzepatide
by: Mark L. Hartman, et al.
Published: (2025-08-01)